ProfileGDS5678 / 1438663_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 89% 89% 90% 88% 88% 90% 90% 89% 89% 90% 89% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0942590
GSM967853U87-EV human glioblastoma xenograft - Control 26.9918689
GSM967854U87-EV human glioblastoma xenograft - Control 37.0781789
GSM967855U87-EV human glioblastoma xenograft - Control 47.4684990
GSM967856U87-EV human glioblastoma xenograft - Control 56.9323688
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5494988
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9944990
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.094890
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.061289
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0430889
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1707190
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1800989
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3922991
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1704590